{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:59:23Z","timestamp":1787065163999,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016820","name":"Vaccine Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.intimp.2021.108187","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T02:53:42Z","timestamp":1632797622000},"page":"108187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"PB","title":["The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41"],"prefix":"10.1016","volume":"101","author":[{"given":"Reshma","family":"Perween","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugavelu","family":"PraveenKumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal Ahmed","family":"Parray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-8996","authenticated-orcid":false,"given":"Vanshika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Chiranjivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Jakhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta","family":"Sonar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Reema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Kumar","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandresh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Kumar","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubbir","family":"Ahamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweety","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-938X","authenticated-orcid":false,"given":"Supratik","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-2867","authenticated-orcid":false,"given":"Kalpana","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1-3","key":"10.1016\/j.intimp.2021.108187_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.theochem.2004.02.018","article-title":"Structural similarity between HIV-1 gp41 and SARS-CoV S2 proteins suggests an analogous membrane fusion mechanism","volume":"677","author":"Wu Zhang","year":"2004","journal-title":"Theochem."},{"key":"10.1016\/j.intimp.2021.108187_b0010","unstructured":"Structures and Mechanisms of Viral Membrane Fusion Proteins, n.d.. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2649671\/ (accessed March 17, 2021)."},{"key":"10.1016\/j.intimp.2021.108187_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2180-3-20","article-title":"Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy","volume":"3","author":"Kliger","year":"2003","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.intimp.2021.108187_b0020","unstructured":"Gallaher: Model of the pre-insertion region of the... - Google \u0935\u093f\u0926\u094d\u0935\u093e\u0928, (n.d.). https:\/\/scholar.google.com\/scholar_lookup?journal=Virology&title=Model+of+the+pre-insertion+region+of+the+spike+(S2)+fusion+glycoprotein+of+the+human+SARS+coronavirus:+implications+for+antiviral+therapeutics&author=W.R.+Gallaher&author=R.F.+Garry&publication_year=2003& (accessed May 12, 2021)."},{"issue":"9","key":"10.1016\/j.intimp.2021.108187_b0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.intimp.2021.108187_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/096876899294706","article-title":"Structural basis for membrane fusion by enveloped viruses","volume":"16","author":"Weissenhorn,","year":"1999","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.intimp.2021.108187_b0035","doi-asserted-by":"crossref","first-page":"14991","DOI":"10.1038\/s41598-020-71748-7","article-title":"Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition","volume":"10","author":"Grant","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2021.108187_b0040","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-020-16567-0","article-title":"Vulnerabilities in coronavirus glycan shields despite extensive glycosylation","volume":"11","author":"Watanabe","year":"2020","journal-title":"Nat. Commun."},{"issue":"45","key":"10.1016\/j.intimp.2021.108187_b0045","doi-asserted-by":"crossref","first-page":"eabc9999","DOI":"10.1126\/sciadv.abc9999","article-title":"Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals","volume":"6","author":"Zhu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2021.108187_b0050","doi-asserted-by":"crossref","first-page":"108020","DOI":"10.1016\/j.intimp.2021.108020","article-title":"Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus","volume":"99","author":"Murugavelu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2021.108187_b0055","first-page":"ciaa1207","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses","author":"Lustig","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.108187_b0060","article-title":"Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma","author":"Mishra","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2021.108187_b0065","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.1038\/s41598-021-91746-7","article-title":"Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry","volume":"11","author":"Mannar","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2021.108187_b0070","doi-asserted-by":"crossref","unstructured":"S.R. Naik, S.S. Kumar, A. Mittal, S. Swain, S. Ranjan, M. Soneja, S. Sinha, N. Nischal, P. Jorwal, P. Chaturvedi, N. Wig, Seroprevalence of COVID-19 in HIV Population, 2021. https:\/\/doi.org\/10.1101\/2021.06.17.21259066.","DOI":"10.1101\/2021.06.17.21259066"},{"issue":"36","key":"10.1016\/j.intimp.2021.108187_b0075","doi-asserted-by":"crossref","first-page":"12814","DOI":"10.1074\/jbc.AC120.014918","article-title":"Identification of an anti-SARS-CoV-2 receptor binding domain directed human monoclonal antibody from a na\u00efve semi-synthetic library","volume":"295","author":"Parray","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2021.108187_b0080","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.vaccine.2018.01.081","article-title":"Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response","volume":"36","author":"Shrivastava","year":"2018","journal-title":"Vaccine."},{"issue":"7","key":"10.1016\/j.intimp.2021.108187_b0085","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1128\/JVI.03090-15","article-title":"Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop","volume":"90","author":"Patil","year":"2016","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.intimp.2021.108187_b0090","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1074\/jbc.M117.776419","article-title":"Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein","volume":"292","author":"Ahmed","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2021.108187_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3136","article-title":"A rapid novel strategy for screening of antibody phage libraries for production, purification, and functional characterization of amber stop codons containing single-chain antibody fragments","volume":"37","author":"Perween","year":"2021","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.intimp.2021.108187_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641447","article-title":"Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model","volume":"12","author":"Shrivastava","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.108187_b0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1472-6750-12-87","article-title":"A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C","volume":"12","author":"Kumar","year":"2012","journal-title":"BMC Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108187_b0110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12010-018-2862-8","article-title":"Isolation and Characterization of Cross-Neutralizing Human Anti-V3 Single-Chain Variable Fragments (scFvs) Against HIV-1 from an Antigen Preselected Phage Library","volume":"187","author":"Kumar","year":"2019","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.intimp.2021.108187_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12977-016-0312-7","article-title":"Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes","volume":"13","author":"Das","year":"2016","journal-title":"Retrovirology."},{"key":"10.1016\/j.intimp.2021.108187_b0120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virol.2017.07.001","article-title":"Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505","volume":"510","author":"Das","year":"2017","journal-title":"Virology."},{"key":"10.1016\/j.intimp.2021.108187_b0125","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.mex.2019.04.013","article-title":"Method to identify efficiently cleaved, membrane-bound, functional HIV-1 (Human Immunodeficiency Virus-1) envelopes","volume":"6","author":"Samal","year":"2019","journal-title":"MethodsX."},{"key":"10.1016\/j.intimp.2021.108187_b0130","doi-asserted-by":"crossref","unstructured":"A. Izvorski, Predicted 3D Models of the SARS-CoV-2 Spike Protein Membrane Proximal External Region and Transmembrane Domain, 2020. https:\/\/doi.org\/10.26434\/chemrxiv.12923942.v1.","DOI":"10.26434\/chemrxiv.12923942.v1"},{"issue":"39","key":"10.1016\/j.intimp.2021.108187_b0135","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1016\/j.vaccine.2020.07.058","article-title":"Influenza immunization and COVID-19","volume":"38","author":"Maltezou","year":"2020","journal-title":"Vaccine."},{"key":"10.1016\/j.intimp.2021.108187_b0140","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fcimb.2019.00344","article-title":"The Quest for a Truly Universal Influenza Vaccine","volume":"9","author":"Jang","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108187_b0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/bmjebm-2020-111549","article-title":"Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil","volume":"26","author":"Fink","year":"2021","journal-title":"BMJ Evid. Based Med."},{"key":"10.1016\/j.intimp.2021.108187_b0150","unstructured":"The effect of influenza vaccination on trained immunity: impact on COVID-19 | medRxiv, (n.d.). https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.14.20212498v1 (accessed March 17, 2021)."},{"issue":"11","key":"10.1016\/j.intimp.2021.108187_b0155","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.cell.2021.04.042","article-title":"Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies","volume":"184","author":"Williams","year":"2021","journal-title":"Cell."},{"issue":"8","key":"10.1016\/j.intimp.2021.108187_b0160","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrmicro1707","article-title":"Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy","volume":"5","author":"Balzarini","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.intimp.2021.108187_b0165","unstructured":"Structure of 2G12 Fab2 in Complex with Soluble and Fully Glycosylated HIV-1 Env by Negative-Stain Single-Particle Electron Microscopy, (n.d.). https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4136306\/ (accessed March 17, 2021)."},{"issue":"7815","key":"10.1016\/j.intimp.2021.108187_b0170","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.intimp.2021.108187_b0175","article-title":"Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV","author":"Ladner","year":"2020","journal-title":"BioRxiv."},{"issue":"12","key":"10.1016\/j.intimp.2021.108187_b0180","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/CVI.00278-10","article-title":"Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum","volume":"17","author":"Gorse","year":"2010","journal-title":"Clin Vaccine Immunol."},{"issue":"2013","key":"10.1016\/j.intimp.2021.108187_b0185","first-page":"130","article-title":"Cross-reactive antibodies in convalescent SARS patients\u2019 sera against the emerging novel human coronavirus EMC by both immunofluorescent and neutralizing antibody tests","volume":"67","author":"Chan","year":"2012","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2021.108187_b0190","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijid.2020.10.104","article-title":"High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa","volume":"102","author":"Tso","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.108187_b0195","unstructured":"Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry | bioRxiv, (n.d.). https:\/\/www.biorxiv.org\/content\/10.1101\/2021.01.03.425141v1 (accessed March 17, 2021)."},{"issue":"9","key":"10.1016\/j.intimp.2021.108187_b0200","doi-asserted-by":"crossref","DOI":"10.1136\/jclinpath-2020-206942","article-title":"Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results","volume":"74","author":"Tan","year":"2021","journal-title":"J. Clin. Pathol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921008237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921008237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:38:48Z","timestamp":1761586728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921008237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"alternative-id":["S1567576921008237"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108187","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108187"}}